Risk Analysis in Cardiovascular Healthcare Systems Using Machine Learning for Better Clinical Decision Support

Michidmaa Arikhad[1], Aftab Tariq[2], and Saad Rasool[3]

[1]Department of Computer Science, American National University, Louisville Kentucky, USA
[2, 3]Department of Computer Science and Engineering, American National University, Virginia, USA

Correspondence should be addressed to Michidmaa Arikhad; arikhadmichidmaa@gmail.com

ABSTRACT- Cardiovascular disease is one of the leading causes of death worldwide. Many people develop heart problems without any early warning signs. Because of this, the risk analysis is very important in healthcare if it is correct and early. Traditional risk scores are often simple and incorporate a small number of factors. These methods may not be effective with all patients and populations.

Machine learning has become a useful tool for cardiovascular risk analysis. It can research massive amounts of data regarding health and discover concealed patterns. Machine learning models can use data from electronic health records, medical images, ECG signals and wearable devices. Such models could be useful in predicting the risk of heart disease more accurately at an earlier stage and help doctors more accurately predict the risk of heart disease.

This review paper is dedicated to study the recent work on machine learning methods for cardiovascular risk analysis. It discusses common sources of data, preprocessing techniques, and model types. Traditional machine learning models and deep learning methods are both discussed. The paper also describes how these models are applied in clinical decision support systems to assist doctors in making better decisions.

In addition, this review raises important issues such as model validation, explainability, fairness and trust. Many challenges remain, however, including data quality issues as well as lack of real-world testing. Future research directions are also discussed, including explainable AI and privacy-preserving learning.

Overall, this review demonstrates that machine learning has the potential to enhance cardiovascular risk analysis and aid in clinical decision-making. However, careful designing and clinical validation is required before widespread adoption.

KEYWORDS- Cardiovascular Disease, Risk Analysis, Machine Learning, Clinical Decision Support, Healthcare Data, Explainable Artificial Intelligence

I. INTRODUCTION

Cardiovascular disease is a major health problem throughout the world. It affects millions of people every year. Heart attacks, strokes and other heart-related conditions cause the death of a lot of people and long-term disability [1]. These diseases do not affect only older people. Younger adults are also at risk for infection, although on a less frequent basis. Due to this reason, cardiovascular disease places a heavy burden on patients, families and healthcare systems.

Over the past few decades, the global burden of cardiovascular disease has continued to increase. Many countries report increasing number of cases every year [2]. Population growth and increased life expectancy also contribute to this increase. Figure 1 illustrates the fact that cardiovascular disease is a major health problem in all chosen countries, with a higher level of the type of disease in Germany and U.S. but still significant in other countries such as Japan, UK and China. This increasing burden places pressure on healthcare systems and reveals the need to detect risk early and avoid serious outcomes by using better clinical decision support tools.

Cardiovascular risk is determined by many factors. These include high blood pressure, diabetes, obesity, smoking, poor diet and lack of physical activity [3]. Environmental and social factors are also a part of this. The effect of such risk factors is not similar in all areas. Low and middle-income countries are often at a higher risk, as they may not have access to healthcare and prevention programs [4]. This makes early and correct analysis of the risk very important on a global level?

Traditionally, cardiovascular risk assessment is based on the use of clinical risk scores. Common examples include Framingham risk score and other risk score based on guidelines. These methods employ a limited number of factors such as age, sex, cholesterol level and blood pressure [5]. While these tools are simple and easy to use, they have obvious limitations. They often assume that risk factors affect all patients in the same way. This is not true in real life.

Figure 1: Cardiovascular Disease among Top Health Issues in U.S.

Traditional risk scores also have a hard time with complex patient data. They are not able to easily process large data sets and long-term health records [6]. Important information from medical images, ECG signals or wearables is often disregarded. In addition, these models may not be able to perform well for patients who are from different ethnic backgrounds or social backgrounds. As a result, some high-risk patients may not be detected early, while others will be classified incorrectly.

In the last years, machine learning has become prominent in healthcare. The large and complex data sets can be analyzed with machine learning methods [7]. They are able to find patterns that are hard for humans to detect. In the healthcare field of cardiovascular, machine learning models can utilize data from electronic health records, lab tests, imaging tests, ECG signals, and wearable sensors [8]. This provides for a more detailed and personal view of patient risk.

Machine learning models are also flexible. They can be modified as new information becomes available. This makes them amenable to continuous risk monitoring [9]. When combined with clinical decision support systems, these models can help doctors to make better decisions. They can be used to support early diagnosis, risk stratification and treatment planning. However, these models must be reliable, transparent and clinically validated.

The aim of this review is to examine the use of machine learning in the analysis of cardiovascular risks. This paper provides a review of common data sources, modeling approaches and clinical applications. It also covers the challenges related to data quality, explainability, and fairness. By summarizing existing research and highlighting gaps in the literature, this review is intended to help inform future research in this area. The overall focus is around the improvement of clinical decision support and patient care through improved risk analysis.

Figure 2 presents the global burden of cardiovascular disease and trends between 1990 and 2023. Cardiovascular Disease is a rising burden of health worldwide and there is a substantial rise in the number of disability-adjusted life years since the burden of cardiovascular disease began. The burden varies by region, and is higher in low and middle-income countries. Both males and females exhibit a continuous increase in the burden of disease. Most of this burden is from risk factors that can be reduced, which shows the need for data driven and advanced risk assessment methods aside from traditional clinical tools.

Figure 2: Global Burden of Cardiovascular Disease, Trends, and Risk Factors (1990–2023)

II. CLINICAL BACKGROUND OF CARDIOVASCULAR RISK ASSESSMENT

Cardiovascular risk assessment is an assessment that is used to determine the likelihood that a person would develop heart disease. Doctors use this assessment to make prevention and treatment decisions [10]. The idea is to identify those who are at higher risk before serious events such as heart attack or stroke occur. Understanding clinical background of risk is important before computation of machine learning method.

Risk in cardiovascular can be categorized in short term risk and long-term risk. Short-term risk normally refers to the likelihood of a heart event occurring in the next five or ten years [11]. This type of risk is often used to make immediate treatment decisions. Long-term risk focuses on the possibility of developing heart disease over a longer period of time, such as twenty or thirty years [12]. Long-term risk is particularly important for people who are younger and therefore may not show symptoms yet, but have a hidden risk.

Risk assessment is also associated with prevention strategies. Primary prevention is focused on people who have not got heart disease [13]. The goal is to decrease risk factors at early stages and prevent the first heart event. This includes changes to your lifestyle and in some cases medication. Secondary prevention is for those patients who already have heart disease. The aim is to avoid further events, minimize the complications and quality of life [14]. Risk assessment helps the doctors to decide how aggressive treatment should be in both cases.

Many clinical factors affect the risk for cardiovascular disease. Common medical factors include high blood pressure, high cholesterol, diabetes, obesity. Age and sex also play an important role [15]. Family history of heart disease is also a risk factor. Lifestyle factors are also important. Smoking, poor diet, a lack of physical activity and high levels of stress all contribute to the likelihood of having heart disease [16]. These factors often interact with each other, so risk assessment is more complex.

Cardiovascular risk is not the same for everyone. Differences in population are a big factor. Risk differs

according to age group, sex, ethnicity and geographic region. Persons residing in low-income environments may also be at an increased risk of developing it, because of poor access to healthcare and healthy food [17]. Social factors, like education, income and living conditions, also impact the health of the heart [18]. These differences result in inequality within cardiovascular outcomes between populations.

Traditional clinical methods of risk assessment fail to capture this diversity. Many tools have been created based on information from certain populations and may not function well for other populations. This can result in under or over estimation of risk in some groups of people. As a result, some patients may not be given timely care.

A good knowledge of clinical risk factors and population differences is necessary for the improvement of cardiovascular cares. This background also emphasizes why more flexible and data-driven approaches are required. Machine learning techniques hold the potential to manage complex patterns of risk and different populations [19]. However, such methods must be founded on a solid clinical knowledge to ensure safe and effective use.

III. DATA SOURCES AND DATA PREPROCESSING IN CARDIOVASCULAR HEALTHCARE SYSTEMS

Machine learning models have a strong dependence on data quality. In cardiovascular healthcare, there are many sources of data. Each source has different information regarding the health of a patient's heart [20]. It is important to understand these data sources before the construction of risk prediction models.

Electronic health records are a popular source of data. They are patient age, sex, medical history, lab results, and medication use. These records are accumulated over a period of time and give a detailed picture of patient health [21]. However, electronic health records are typically prone to missing values and errors [22]. The data may also be stored in different formats which further makes it difficult to analyze.

ECG data is another important source to analyze cardiovascular risks. ECG signals are signals that capture the electrical activity of the heart. They are good to check for abnormal heart rhythms and early signs of heart diseases [23]. ECG data tends to be applied over time and results in huge amounts of data. Noise and signal distortion are the problems, and you need to handle them carefully.

Medical imaging data is being widely used in the field of cardiovascular care. This includes echocardiography, CT scans and MRI images. These images give detailed information on the structure and function of the heart [24]. Imaging data is extremely rich and complicated. It requires special processing methods and large computing resources. Wearable devices in heart health monitoring are gaining popularity. These devices capture information about heart rate, physical activity and sleep patterns [25]. Wearable Data enables continuous monitoring outside of institutions. However, this data may be noisy and inconsistent, as a result of device errors or user behavior.

Before the machine learning models can be trained, the raw data must be preprocessed. Preprocessing helps in improving the quality of the data and also enhance the performance of the model. Common steps are data cleaning, normalization and missing value handling [26]. Cleaning is done to get rid of the incorrect records or duplicate records. Normalization is a process of scaling the data in such a way that different features can be compared fairly.

Another major problem in cardiovascular datasets is data imbalance. In many cases, the number of healthy patients is much larger than patients with heart disease [27]. This imbalance can lead to poor performance of models in high-risk patients. Techniques such as resampling and weighting are usually employed to address this issue.

The feature selection and extraction are important steps in preprocessing. Feature selection is the process of selecting most important variables for prediction [28]. This helps to reduce the noise and model complexity. Feature extraction generates new features from raw data such as patterns from ECG signals or from image features from scans. These steps help models to learn more meaningful information.

A typical machine learning pipeline for cardiovascular risk classification is represented in Figure 3. Raw clinical data is first cleaned up and prepared. Important features are then picked up or extracted. Sampling methods are used to deal with the problem of data imbalance. The processed data is used to train machine learning models. The last output is a prediction of the presence or absence of heart disease. This pipeline demonstrates how careful data processing and modeling work in conjunction with one another to support reliable clinical decision making.

Figure 3: Machine Learning Pipeline for Cardiovascular Risk Classification

IV. MACHINE LEARNING MODELS FOR CARDIOVASCULAR RISK PREDICTION

Machine learning models are very popular in predicting cardiovascular risk. These models are used to provide doctors with an idea of the likelihood of heart diseases as per the patient's data [29]. Different types of machine learning models are available. Each model has its own advantages and disadvantages. The selection of model depends on data type, clinical objective and resources available.

A. Traditional Models in Machine Learning

Traditional machine learning models are well used in early cardiovascular risk studies. These models are the logistic regression, decision trees, support vector machines, and k-nearest neighbors. They typically work with structured data such as age, blood pressure, cholesterol level, and medical history.

Logistic regression is one of the most popular models. It is simple and easy to understand. Doctors often prefer it because it reveals the effect of each factor on risk [30]. However, it may not work well when relations between factors are complex. Decision trees separate data into simplistic rules. They are simple to interpret and can be used to work with non-linear patterns [31]. However, they may become unstable and overfit the data. Support vector machines are useful with small and medium sized data. They work well with clear class boundaries but have to be careful with the parameters used.

The traditional models are fast and they require less computing power. They are suitable for clinical settings that have limited resources. However, their performance tends to be much lower when data becomes large, complex or high-dimensional.

B. Deep Learning Approaches

Deep learning models have become increasingly common in cardiovascular risk prediction. These models have the ability to learn complex patterns from large datasets. They are particularly useful in the case of unstructured data like ECG signals and medical images [32]. Convolutional neural networks are extensively used for image analysis and ECG analysis. They are able to extract important features automatically without any manual effort. This helps to increase accuracy of the prediction [33]. Recurrent neural network and long short-term memory models are used for time-based data. They are able to model patient health changes over time.

Deep learning models can also be used to combine different types of data. For example, clinical data can be used in combination with ECG or imaging data. This gives a more complete picture of patient risk [34]. However, deep learning models tend to be hard to interpret. They need along large data sets and computing power. Because of their complexity, deep learning models are more difficult to implement in a real clinical setting. Lack of transparency can also lead to lack of trust among doctors. Such problems restrain their use for their strong performance.

C. Ensemble and Hybrid Models

Ensemble models: Ensemble models are a combination of different machine learning models that help in improving the performance. Some of the popular ensemble techniques are random forests and gradient boosting models [35]. These models reduce the error by averaging/weighting the predictions of different learners.

Random forests are very popular for studies of cardiovascular risk. They deal well with missing data and lessen the overfitting problem. Gradient boosting models

like XGBoost are known to often attain high accuracy of say 90 % [36]. They work well on structured clinical data. Hybrid models are those that use traditional clinical risk scores along with the outputs of machine learning. This approach is useful to preserve clinical interpretability while enhancing the prediction accuracy. Hybrid systems are helpful for progressive adoption for healthcare environments.

It is important to choose the right machine learning model. Accuracy alone is not enough. Models must also be reliable and interpretable and easy to use. Clinical acceptance requires trust and transparency. Data size and type have a great effect on the choice of model. Small datasets favour simpler models. Large and complex data sets are being used to support deep learning techniques. Computing resources and real-time needs also need to be taken into account. Models should be tested on different populations to be fair. Over fitting and bias need to be avoided. Clinical validation is needed before deployment.

Table 1: Summary of Machine Learning Models Used for Cardiovascular Risk Prediction

Model Type	Data Modality	Clinical Task	Strengths	Limitations
Logistic Regression	EHR, labs	Risk prediction	Simple, interpretable	Limited with complex data
Decision Trees / Random Forest	EHR, ECG, imaging	Risk classification	Handles non-linear patterns	Can overfit
Support Vector Machines (SVM)	EHR, ECG	Classification	Works well with small datasets	Hard to interpret
Convolutional Neural Networks (CNN)	Imaging, ECG signals	Detect patterns	High accuracy for images	Needs large data, less interpretable
Recurrent Neural Networks (RNN) / Transformers	Time-series EHR, ECG	Predict future events	Handles sequential data	Complex, hard to interpret
Ensemble / Hybrid Models	EHR + Imaging + ECG	Risk prediction	Combines strengths of models	Computationally heavy

Table 1 summarizes some of the most commonly used machine learning algorithms for cardiovascular risk prediction. It compares traditional, deep learning, and ensemble methods. The table illustrates how various models operate with data such as electronic health records, ECG and medical images. While advanced models can offer a higher accuracy, they can also lack interpretability and require additional resources. This comparison stresses the need to balance the model's performance with its usability in the clinical setting.

V. CLINICAL DECISION SUPPORT SYSTEMS POWERED BY MACHINE LEARNING

A. CDSS Architecture and Components

Clinical decision support systems (CDS) are helping doctors to make better decisions. These systems use data from patients from numerous sources. Data can be collected from electronic health records, lab data, imaging, ECG signals, as well as wearable devices [37]. Machine learning models are an important part of CDSS. They are able to study patient data and identify patterns that humans may not notice. The system typically has many layers. First is the data input layer, which gathers all the information of the patient. Then comes the preprocessing which cleans the data, fills the missing values, and prepares it for analysis. The modeling layer uses machine learning algorithms to determine the patient's risk of heart disease [38]. Some systems have explainable AI layers built into the system to explain why the system made a particular prediction. Validation layers are used to verify the accuracy of the predictions before they are sent to the doctor.

These layers work together to make CDSS reliable. The goal is to assist doctors in making decisions faster and more accurately. By using several sources of data and advanced models, CDSS can help in the early detection of heart problems. This helps to improve patient care and minimizes the likelihood of serious complications.

B. Stratification and Alerts (risk)

One important feature of CDSS is risk stratification. The system can group the patients according to how much they are at risk for heart disease. High risk patients receive additional attention and may be early treated. Medium-risk patients may receive lifestyle information, observation or prevention. Low-risk patients are typically followed by routine care [39]. This grouping helps doctors to focus their resources where they are most needed.

CDSS can also send alerts to doctors if the risk of the patient changes [40]. For example, if a patient's blood pressure suddenly goes up or lab results reveal there are new problems, the system can alert the doctor. Alerts enable doctors to act swiftly and avoid serious events. By providing timely warnings, the system assists doctors in dealing with patients more effectively.

The use of risk stratification and alerts is also making care more personalized. Each patient is treated based on his or her risk. Doctors can adjust treatment plans, schedule follow-ups or recommend lifestyle changes based on the system's suggestions. This approach can help to make patient care safer and more effective.

C. Human-AI Collaboration

Machine learning in CDSS does not replace doctors. Instead, it supports them. The system provides a prediction, explanation, and suggestions, but the doctor makes the final decision [41]. Doctors use their knowledge and experience along with the output of the model. Explainable AI reveals which features had an impact on a patient's risk score. For example, abnormal blood pressure or abnormal ECG measurements may be highlighted. This transparency helps doctors to trust the system and make better decisions.

Collaboration between human and AI is important to safe care. Doctors can confirm or make adjustments according to the condition and preferences of the patient [42]. It is also possible for them to explain the decisions to the patient. The combination of insights from AI and the judgment of humans bring about better results. It is to ensure that predictions will be used in a safe clinical situation.

CDSS also helps doctors to learn from data. Over time, with more patient information, the system is able to make better predictions [43]. These are valuable insights for doctors who can use them to recognise patterns of risk earlier. This is a continuous learning process that reinforces clinical practice.

An example of a typical explainable AI-enabled CDSS is shown in Figure 4. Patient data from various sources is gathered and run through machine learning models. Important features are highlighted and explained for the clinician using AI layers. The system provides risk scores for each patient and is able to send alerts if a patient is at high risk. Validation and performance layers ensure that the predictions are correct before the results are displayed to doctors. This figure shows the integration of machine learning and explainable AI by CDSS to enhance clinical decision making without making it unsafe or unreliable.

Figure 4: Explainable AI–Enabled Clinical Decision Support Architecture

VI. MODEL EVALUATION, VALIDATION, AND CLINICAL UTILITY

The machine learning models can help predict the presence of heart disease and aid physicians in clinical decision-making [44]. But prior to their application in hospitals, it is highly imperative to determine whether they are effective. This is called evaluation. Performance demonstrates the level of correctness and fidelity of the model. It also aids in determining the strengths and weaknesses. Close consideration will make sure that the model does not make false predictions that may be detrimental to patients.

A. Performance Measures

The check of the performance of a model is done through several measures. AUC or Area Under Curve is one of the measures. AUC demonstrates the capability of the model to distinguish between the high-risk and low-risk patients. An increase in AUC indicates that the model has a greater ability to identify at-risk patients [45].

Another significant measure is sensitivity. It informs us of the number of high-risk patients that the model identifies correctly [46]. Low sensitivity model may overlook patients that require assistance, which is a hazardous situation. It is also necessary in calibration. Calibration tests are used to check whether the risk predicted is as it is happening in reality [47]. To illustrate, when the model predicts that the risk of having a heart attack is 20% then about 20 among 100 patients should have a heart attack. Calibration Good calibration doctors makes the model reliable to doctors.

The application of a multi-measure provides a full picture of the performance of the model. As an example, one model can have high AUC and poor calibration. The evaluation of several metrics will guarantee the reliability and safety of the use of the model in clinical practice.

B. Validation

Validation determines how well the model performs on external data. Validation can be of two main types, which are internal and external.

Internal validation evaluates the model on the same data that the model was trained on. It uses such techniques as cross-validation or data division into training and testing portions [48]. This is used to check whether the model can learn without overfitting.

External validation is used to test the model on new data of other hospitals, clinics or populations. This is quite critical as it demonstrates whether the model is general and reliable. The model that has performed well on the original data might not perform when applied with new patients. External validation makes the model trustworthy in real life scenarios.

C. Dataset Bias

The issue of dataset bias is typical in machine learning. In other cases, the data to train the model are not balanced [49]. As an example, a high number of patients with heart disease might not be more than healthy ones. This may worsen the prediction of high-risk cases by the model.

Lack of diversity is another issue. In case the dataset is not representative of all age groups, genders, ethnicities, or regions, the model will not work well with some of the populations [50]. Generalizability is enhanced by ensuring the balance and diversity of information. A model that is

generalizable is effective with more patients and other hospitals.

D. Clinical Utility

Clinical utility concerns itself with the utility of the model in practical healthcare. A model must be accurate, in addition, it must aid in making better choices by doctors [51]. An example is a high-risk patient that a model can recognize and require more attention or prompt treatment. Clinical trials or retrospective studies should be done on models. Clinical trials test the improvement of patient outcomes with the use of the model. Retrospective studies examine previous patient information to determine whether the model would have performed the right predictions or not. These tests reveal whether the model is safe to be applied in hospitals.

E. Issues and Problems

There are still some challenges despite evaluation and validation. Models may be complex enough as to be beyond the grasp of the doctor. It is important to explain why clinicians can trust the decisions made by the model. Their constant surveillance is also required. Models might require revision as patient information and health trends can evolve. Also important are ethical considerations. The model is not supposed to provide discriminatory forecasts on some groups. Patient data privacy has to be ensured at all times. Clinical practice should only be applied to models which are accurate, generalizable, explainable and safe.

Machine learning in cardiovascular healthcare is important in evaluation, validation, and clinical utility. Performance indicators like AUC, sensitivity, and calibration indicate the predictive ability of risk using the model. Validation helps to verify that the model is applicable to new patients and it is predictive beyond the training data. Resolving the dataset bias and diversity enhances the fairness of the model. Lastly, clinical utility evaluates whether the model is really beneficial to the actual doctors and patients in actual healthcare. Careful testing and only then with careful testing can the change be introduced.

VII. EXPLAINABILITY, ETHICS AND TRUST IN CARDIOVASCULAR RISK ANALYSIS

A. Explicability of Machine Learning Models

Doctors should be aware of how a machine learning model takes predictions even though it may be highly accurate. This is what is known as explainability. Explainable models demonstrate why a prediction has been made [52]. In this case, they are able to point at the risk factors that were the most predictive of heart disease. Such techniques as SHAP and LIME are usually employed. Such approaches emphasize significant characteristics, including high blood pressure, cholesterol, age, or diabetes, which determine the output of the model [53].

Explainable AI makes doctors feel comfortable in the use of machine learning tools. Lacking explainability, a model could be true and still not trusted by doctors. This may cause them to be reluctant to use the model to take care of the patients. Doctors are able to check a prediction after knowing the reason behind it by using their clinical knowledge. Explainability can also be used to explain outcomes to patients and their caregivers to enhance communication and joint decision-making.

B. Trade-off between Performance and Interpretability

Performance vs. interpretability is usually a tradeoff. There are models, like deep learning networks, which are able to recognize extremely complicated patterns. They are able to be very precise in forecasting risk of cardiovascular disease. But they are not easy to comprehend. The model has a black box aspect of decision process.

Some models are easier to understand such as a decision tree or a logistic regression. Physicians are able to visualize the influence of every variable on the risk [54]. However, deep learning models can be better than simpler models. There is a need to strike a balance in the clinical practice. The models should be accurate enough and understandable enough to be trusted. Explainable AI assists in enhancing the transparency of even the complex models.

C. Ethical Considerations

Ethics is crucial to machine learning in healthcare. Models should be fair and not show favoritism towards one group more than another. Bias may arise if the data used to train the model is unbalanced [55]. For example, when the majority of the data used in training is from men, the model may not perform well for women. Similarly, models trained on data from one part of the world may not work for people from other parts of the world or ethnic groups.

Ethical AI also requires privacy and consent. Patient data is private and sensitive. Hospitals and researchers need to ensure that data is safe and used with consent [56]. Personal information is never to be shared without consent. Maintaining patient privacy is critical to building patient trust in AI systems.

Trust is the most important element in adopting machine learning in hospitals. Doctors need to believe in correct and safe predictions [57]. Explainable AI helps to build trust by explaining why the model made a specific prediction. Transparency gives clinicians the opportunity to compare the model with their own experience.

Healthcare organizations are also useful for building trust. Hospitals frequently have review boards that examine AI models before they are implemented in patient care. Governments and regulators develop rules to ensure that AI tools are safe and of high quality. Following these rules make models more reliable and trustworthy.

D. Regulatory Guidelines

Regulations are required to ensure that AI tools are safe. In many countries, hospitals and medical authorities must approve systems based on machine learning before they can be used [58]. These regulations include safety, accuracy, data privacy, and ethics. Machine learning models should also be updated and monitored on a regular basis to ensure that they continue to function properly and safely. Compliance with regulations helps lower the risk of errors and increases patient outcomes.

This visualization helps doctors to understand the model. They can understand which risk factors are most important for a patient. This way they can validate or challenge the outcomes. Explainable AI also helps to communicate with patients. Patients can know why they are at high risk or low risk, which aids in lifestyle changes and adherence to treatment.

Explainability, ethics, and trust are the keys to machine learning in cardiovascular care. Even the most accurate model cannot be sufficient if doctors cannot understand it

[59]. Explainable AI tools such as SHAP and LIME help to ensure that predictions are understandable and clear. Ethical issues, such as fairness, privacy, and consent, need to be addressed. Trust is built through transparency, hospital review, and compliance with regulations.

By combining accurate machine learning with explainability and ethical practices, AI systems can help in supporting better decision-making. They can help doctors to identify high-risk patients early, explain results to patients and guide treatment safely. This makes machine learning a valuable tool in improving cardiovascular care.

VIII. OPEN CHALLENGES AND FUTURE RESEARCH DIRECTIONS

Machine learning has had great promise in cardiovascular risk analysis. However, there are still many challenges that prevent it from being used extensively in the real world of healthcare. One of the biggest problems is the quality of the data. Medical records and ECG signals as well as the imaging data frequently contain missing values, errors, or inconsistent formats [60]. Poor quality data can result in machine learning models that are less accurate. Another problem is that many models are trained using data from a small or specific population. This means they may not be

working well for other groups or regions. Lack of generalizability can make doctors less trustworthy of these models.

The other key problem is explainability. Many machine learning models, in particular deep learning models, work like a "black box" [61]. Doctors may not be able to understand how the model makes predictions. This decreases trust and slows down clinical adoption. Ethical issues are also important. Bias in the data can result in unfair predictions. Patients belonging to some ethnic or social groups may be misclassified. Privacy concerns are another obstacle. Patient data will need to be safeguarded but without compromising the ability of models to learn information that's useful.

Table 2 summarises the main challenges and highlights potential future directions of research. As highlighted in the table, some of the challenges are data quality, model generalizability, interpretability, bias, and privacy. Future research can focus on federated learning-to train models without sharing sensitive data, multimodal modeling-to combine different types of patient data, and explainable AI-to make predictions transparent for clinicians. Overcoming these challenges is the key to bring machine learning from the lab to actual clinical practice.

Table 2: Challenges and Future Directions in ML-Based Cardiovascular Risk Analysis

Challenge	Description	Clinical Impact	Potential Research Direction
Data quality	Missing, noisy, or inconsistent data	Reduces model accuracy	Data cleaning, standardization, preprocessing
Generalizability	Models trained on limited populations	Poor performance in different groups	Use diverse datasets, external validation
Explainability	Black-box models	Low clinician trust	Develop interpretable and explainable AI methods
Bias & fairness	Unequal predictions for certain groups	Inequitable care	Bias detection, fairness-aware algorithms
Privacy	Sensitive patient data	Limits data sharing	Federated learning, privacy-preserving techniques

IX. CONCLUSION

Cardiovascular disease is a health issue of significant concern globally. The burden has been growing over the years particularly in the low- and middle-income nations. Risk scores are old-fashioned and have numerous constraints. They are unable to completely record complicated patient data or population variations. These drawbacks can be overcome with machine learning models. They are able to utilize vast and varied data and uncover latent patterns and make more precise risk forecasts.

Clinical decision support systems should be used together with machine learning. Prediction explanations through explainable AI can assist physicians to comprehend it and these fosters trust and increases adoption. Patient outcomes may be enhanced with the assistance of continuous monitoring and individual risk evaluation to implement early interventions.

Though there is improvement, there are still problems. There are data quality, model generalizability and bias. Ethical concerns and privacy are also crucial. The further study should be aimed at making it explainable, integrating various sources of data, and creating a technique that can be

applicable to different groups of people. Successful collaboration among clinicians, engineers and data scientists is a necessity.

In general, machine learning can revolutionize cardiovascular risk assessment and clinical decision support. It can assist doctors to make more appropriate choices, enhance patient care and decrease the overall burden of cardiovascular disease globally, only in case it is carefully designed, validated, and implemented.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

REFERENCES

[1] World Health Organization, "Cardiovascular diseases (CVDs)," World Health Organization, Jul. 31, 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

[2] B. Chong et al., "Global burden of cardiovascular diseases: projections from 2025 to 2050," *European Journal of Preventive Cardiology*, Sep. 2024. Available from: https://doi.org/10.1093/eurjpc/zwae281

[3] Dumitrescu et al., "Cardiovascular Risk Factors in Socioeconomically Disadvantaged Populations," *Biomedicines*, vol. 12, no. 9, pp. 1989–1989, Sep. 2024. Available from: https://doi.org/10.3390/biomedicines12091989

[4] H. Phelan, V. Yates, and E. Lillie, "Challenges in healthcare delivery in low- and middle-income countries," *Anaesthesia & Intensive Care Medicine*, vol. 23, no. 8, Aug. 2022. Available from: https://doi.org/10.1016/j.mpaic.2022.05.004

[5] M. Amiri et al., "Cardiovascular disease risk prediction by Framingham risk score in women with polycystic ovary syndrome," *Reproductive Biology and Endocrinology*, vol. 23, no. 1, Feb. 2025. Available from: https://doi.org/10.1186/s12958-025-01346-7

[6] K. Batko and A. Ślęzak, "The Use of Big Data Analytics in Healthcare," *Journal of Big Data*, vol. 9, pp. 1–24, Jan. 2022. Available from: https://doi.org/10.1186/s40537-021-00553-4

[7] H. Habehh and S. Gohel, "Machine Learning in Healthcare," *Current Genomics*, vol. 22, no. 4, pp. 291–300, Jul. 2021. Available from: https://doi.org/10.2174/1389202922666210705124359

[8] Quer, R. Arnaout, M. Henne, and R. Arnaout, "Machine Learning and the Future of Cardiovascular Care," *Journal of the American College of Cardiology*, vol. 77, no. 3, pp. 300–313, Jan. 2021. Available from: https://doi.org/10.1016/j.jacc.2020.11.030

[9] N. Paltrinieri, L. Comfort, and G. Reniers, "Learning about risk: Machine learning for risk assessment," *Safety Science*, vol. 118, pp. 475–486, Oct. 2019. Available from: https://doi.org/10.1016/j.ssci.2019.06.001

[10] J. Li and X. Lu, "Cardiovascular risk assessment: The key path toward precision prevention," *Chronic Diseases and Translational Medicine*, vol. 9, no. 4, pp. 273–276, Aug. 2023. Available from: https://doi.org/10.1002/cdt3.90

[11] Johar et al., "Changes in 10-Year Predicted Cardiovascular Disease Risk for a Multiethnic Semirural Population in South East Asia," *JMIR Public Health and Surveillance*, vol. 10, p. e55261, 2024. Available from: https://doi.org/10.2196/55261

[12] M. Lloyd-Jones, M. G. Larson, A. Beiser, and D. Levy, "Lifetime risk of developing coronary heart disease," *The Lancet*, vol. 353, no. 9147, pp. 89–92, Jan. 1999. Available from: https://doi.org/10.1016/s0140-6736(98)10279-9

[13] J. Stewart, K. Addy, S. Campbell, and P. Wilkinson, "Primary prevention of cardiovascular disease," *JRSM Cardiovascular Disease*, vol. 9, Jan. 2020. Available from: https://doi.org/10.1177/2048004020949326

[14] S. P. Karunathilake and G. U. Ganegoda, "Secondary Prevention of Cardiovascular Diseases and Application of Technology for Early Diagnosis," *BioMed Research International*, vol. 2018, pp. 1–9, May 2018. Available from: https://doi.org/10.1155/2018/5767864

[15] D. Fuchs and P. K. Whelton, "High Blood Pressure and Cardiovascular Disease," *Hypertension*, vol. 75, no. 2, pp. 285–292, Dec. 2019. Available from: https://doi.org/10.1161/HYPERTENSIONAHA.119.14240

[16] M. Norouzzadeh et al., "Cigarette smoking and cardiovascular disease incidence and all-cause mortality," *BMC Public Health*, vol. 24, no. 1, Apr. 2024. Available from: https://doi.org/10.1186/s12889-024-18468-z

[17] Bazoukis et al., "Impact of Social Determinants of Health on Cardiovascular Disease," *Journal of the American Heart Association*, vol. 14, no. 5, Mar. 2025. Available from: https://doi.org/10.1161/jaha.124.039031

[18] W. M. Schultz et al., "Socioeconomic Status and Cardiovascular Outcomes," *Circulation*, vol. 137, no. 20, pp. 2166–2178, 2018. Available from: https://doi.org/10.1161/circulationaha.117.029652

[19] N. H. Alhumaidi et al., "The Use of Machine Learning for Analyzing Real-World Data in Disease Prediction," *JMIR Medical Informatics*, vol. 13, p. e68898, Jun. 2025. Available from: https://doi.org/10.2196/68898

[20] Kowalewska et al., "Sources of patients' knowledge about cardiovascular disease prevention in Poland," *Advances in Interventional Cardiology*, vol. 18, no. 1, pp. 27–33, Jan. 2022. Available from: https://doi.org/10.5114/aic.2022.116461

[21] W. Wang, D. Ferrari, G. Haddon-Hill, and V. Curcin, "Electronic Health Records as Source of Research Data," PubMed, 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK597466/

[22] B. J. Wells, A. S. Nowacki, K. Chagin, and M. W. Kattan, "Strategies for Handling Missing Data in Electronic Health Record Derived Data," *eGEMs*, vol. 1, no. 3, p. 7, Dec. 2013. Available from: https://doi.org/10.13063/2327-9214.1035

[23] Jandera et al., "ECG Signal Analysis and Abnormality Detection Application," *Algorithms*, vol. 18, no. 11, p. 689, Oct. 2025. Available from: https://doi.org/10.3390/a18110689

[24] P. Z. Manoel et al., "Cardiovascular Imaging in the Era of Precision Medicine," *Health Science Reports*, vol. 7, no. 11, Oct. 2024. Available from: https://doi.org/10.1002/hsr2.70173

[25] Hughes et al., "Wearable Devices in Cardiovascular Medicine," *Circulation Research*, vol. 132, no. 5, pp. 652–670, Mar. 2023. Available from: https://doi.org/10.1161/circresaha.122.322389

[26] L. Ortiz, "Data Preprocessing Techniques for AI/ML-Readiness," *JMIR mHealth and uHealth*, Apr. 2024. Available from: https://doi.org/10.2196/59587

[27] S. B. Akter et al., "Optimizing stability of heart disease prediction across imbalanced learning," *Computer Methods and Programs in Biomedicine*, vol. 265, p. 108702, Mar. 2025. Available from: https://doi.org/10.1016/j.cmpb.2025.108702

[28] L. Hemdanou et al., "Comparative analysis of feature selection and extraction methods," *Computers and Education: Artificial Intelligence*, vol. 7, p. 100301, Dec. 2024. Available from: https://doi.org/10.1016/j.caeai.2024.100301

[29] S. Wan, F. Wan, and X. Dai, "Machine learning approaches for cardiovascular disease prediction: A review," *Archives of Cardiovascular Diseases*, vol. 118, no. 10, May 2025. Available from: https://doi.org/10.1016/j.acvd.2025.04.055

[30] Okolie et al., "Heart Disease Prediction: A Logistic Regression Approach," *Open Journal of Applied Sciences*, vol. 15, no. 11, pp. 3534–3552, 2025. Available from: https://doi.org/10.4236/ojapps.2025.1511229

[31] Luo, M. A. Arshad, and G. Luo, "Decision Trees for Strategic Choice of Augmenting Management Intuition with Machine Learning," *Symmetry*, vol. 17, no. 7, p. 976, Jun. 2025. Available from: https://doi.org/10.3390/sym17070976

[32] R. Khademi, "Deep learning models for predicting heart disease risk using the UCI database," *American Journal of Cardiovascular Disease*, vol. 15, no. 6, pp. 374–386, 2025. Available from: https://doi.org/10.62347/cebk2916

[33] S. Das, M. Epland, J. Yu, and R. Suri, "Interpretation of EKG with Image Recognition and Convolutional Neural Networks," *Current Problems in Cardiology*, vol. 48, no. 8, p. 101744, Aug. 2023. Available from: https://doi.org/10.1016/j.cpcardiol.2023.101744

[34] P. A. Moreno-Sánchez et al., "ECG-based data-driven solutions for diagnosis and prognosis of cardiovascular diseases," *Computers in Biology and Medicine*, vol. 172, Feb. 2024. Available from: https://doi.org/10.1016/j.compbiomed.2024.108235

[35] B. Naderalvojoud and T. Hernandez-Boussard, "Improving machine learning with ensemble learning on observational healthcare data," *AMIA Annual Symposium Proceedings*, vol. 2023, p. 521, Jan. 2024. Available from: https://doi.org/10785929/pdf/146

[36] S. Hossain et al., "Machine learning approach for predicting cardiovascular disease in Bangladesh," *BMC Cardiovascular Disorders*, vol. 24, no. 1, Apr. 2024. Available from: https://doi.org/10.1186/s12872-024-03883-2

[37] R. Sutton et al., "An overview of clinical decision support systems: Benefits, risks, and strategies for success," *NPJ*

Digital Medicine, vol. 3, no. 1, pp. 1–10, 2020. Available from: https://doi.org/10.1038/s41746-020-0221-y

[38] M. Elhaddad and S. Hamam, "AI-Driven Clinical Decision Support Systems: An Ongoing Pursuit of Potential," *Cureus*, vol. 16, no. 4, Apr. 2024. Available from: https://doi.org/10.7759/cureus.57728

[39] S. Miao et al., "The Construction and Application of a Clinical Decision Support System for Cardiovascular Diseases," *JMIR Medical Informatics*, vol. 13, Mar. 2025. Available from: https://doi.org/10.2196/63186

[40] S.-C. Chien et al., "Alerts in Clinical Decision Support Systems (CDSS): A Bibliometric Review," *Healthcare*, vol. 10, no. 4, p. 601, Mar. 2022. Available from: https://doi.org/10.3390/healthcare10040601

[41] A. Gomez-Cabello et al., "AI-Based Clinical Decision Support Systems in Primary Care: A Scoping Review," *European Journal of Investigation in Health Psychology and Education*, vol. 14, no. 3, pp. 685–698, Mar. 2024. Available from: https://doi.org/10.3390/ejihpe14030045

[42] O. Asan, A. E. Bayrak, and A. Choudhury, "Artificial Intelligence and Human Trust in Healthcare: Focus on Clinicians," *Journal of Medical Internet Research*, vol. 22, no. 6, Jun. 2020. Available from: https://doi.org/10.2196/15154

[43] K. N. Singh and J. K. Mantri, "A clinical decision support system using rough set theory and machine learning," *Intelligent Medicine*, vol. 4, no. 3, Apr. 2024. Available from: https://doi.org/10.1016/j.imed.2023.08.002

[44] Y. Mao, B. L. Jimma, and T. B. Mihretie, "Machine learning algorithms for heart disease diagnosis: A systematic review," *Current Problems in Cardiology*, vol. 50, no. 8, May 2025. Available from: https://doi.org/10.1016/j.cpcardiol.2025.103082

[45] K. Hajian-Tilaki, "Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation," *Caspian Journal of Internal Medicine*, vol. 4, no. 2, p. 627, 2024. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3755824/

[46] Shreffler and M. R. Huecker, "Diagnostic Testing Accuracy: Sensitivity, Specificity, Predictive Values and Likelihood Ratios," PubMed, Mar. 06, 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557491/

[47] B. Van Calster et al., "Calibration: the Achilles heel of predictive analytics," *BMC Medicine*, vol. 17, no. 1, Dec. 2019. Available from: https://doi.org/10.1186/s12916-019-1466-7

[48] Wilimitis and C. G. Walsh, "Practical Considerations and Applied Examples of Cross-Validation for Model Development and Evaluation in Health Care," *JMIR AI*, vol. 2, no. 1, p. e49023, Dec. 2023. Available from: https://doi.org/10.2196/49023

[49] Mavrogiorgos et al., "Bias in Machine Learning: A Literature Review," *Applied Sciences*, vol. 14, no. 19, Oct. 2024. Available from: https://doi.org/10.3390/app14198860

[50] Arora et al., "The value of standards for health datasets in AI-based applications," *Nature Medicine*, vol. 29, no. 11, Oct. 2023. Available from: https://doi.org/10.1038/s41591-023-02608-w

[51] Eini-Porat et al., "Tell me something interesting: Clinical utility of machine learning prediction models in the ICU," *Journal of Biomedical Informatics*, vol. 132, Aug. 2022. Available from: https://doi.org/10.1016/j.jbi.2022.104107

[52] Hammann and M. Wouters, "Explainability Versus Accuracy of Machine Learning Models," *European Accounting Review*, Feb. 2025. Available from: https://doi.org/10.1080/09638180.2025.2463961

[53] Pang, "A comparative study of explainable machine learning models with Shapley values for diabetes prediction," *Healthcare Analytics*, vol. 7, Jun. 2025. Available from: https://doi.org/10.1016/j.health.2025.100390

[54] S.-J. Lin et al., "Prediction Models Using Decision Tree and Logistic Regression Method for Predicting Hospital Revisits in Peritoneal Dialysis Patients," *Diagnostics*, vol. 14, no. 6, p. 620, Jan. 2024. Available from: https://doi.org/10.3390/diagnostics14060620

[55] Hanna et al., "Ethical and Bias Considerations in Artificial Intelligence/Machine Learning," *Modern Pathology*, vol. 38, no. 3, 2024. Available from: https://doi.org/10.1016/j.modpat.2024.100686

[56] T. Pham, "Ethical and legal considerations in healthcare AI," *Royal Society Open Science*, vol. 12, no. 5, May 2025. Available from: https://doi.org/10.1098/rsos.241873

[57] J. Yao et al., "Trust transfer from medical AI to doctors and hospitals," *BMC Medical Ethics*, vol. 26, no. 1, Oct. 2025. Available from: https://doi.org/10.1186/s12910-025-01300-7

[58] S. Mohammed and N. Malhotra, "Ethical and Regulatory Challenges in Machine Learning-Based Healthcare Systems," *BenchCouncil Transactions on Benchmarks, Standards and Evaluations*, vol. 5, no. 1, May 2025. Available from: https://doi.org/10.1016/j.tbench.2025.100215

[59] K. Rasheed et al., "Explainable, trustworthy, and ethical machine learning for healthcare: A survey," *Computers in Biology and Medicine*, vol. 149, Oct. 2022. Available from: https://doi.org/10.1016/j.compbiomed.2022.106043

[60] J. Digitale et al., "Methods for Addressing Missingness in Electronic Health Record Data for Clinical Prediction Models," *JMIR Medical Informatics*, vol. 13, Nov. 2025. Available from: https://doi.org/10.2196/79307

[61] Swinckels et al., "The Use of Deep Learning and Machine Learning on Longitudinal Electronic Health Records for the Early Detection and Prevention of Diseases," *Journal of Medical Internet Research*, Apr. 2023. Available from: https://doi.org/10.2196/48320